Is I-metaiodobenzylguanidine Heart-to-mediastinum Ratio Dependent on Age? From Japanese Society of Nuclear Medicine Normal Database

Overview

Journal Ann Nucl Med

Date 2018 Jan 16

PMID 29333564

Citations 12

Authors

Kenichi Nakajima

Koichi Okuda

Shinro Matsuo

Hiroshi Wakabayashi

Seigo Kinuya

Affiliations

Soon will be listed here.

Abstract

Background: Heart-to-mediastinum ratios (HMRs) of I-metaiodobenzylguanidine (MIBG) have usually been applied to prognostic evaluations of heart failure and Lewy body disease. However, whether these ratios depend on patient age has not yet been clarified using normal databases.

Methods: We analyzed 62 patients (average age 57 ± 19 years, male 45%) derived from a normal database of the Japanese Society of Nuclear Medicine working group. The HMR was calculated from early (15 min) and delayed (3-4 h) anterior planar I-MIBG images. All HMRs were standardized to medium-energy general purpose (MEGP) collimator equivalent conditions using conversion coefficients for the collimator types. Washout rates (WR) were also calculated, and we analyzed whether early and late HMR, and WR are associated with age.

Results: Before standardization of HMR to MEGP collimator conditions, HMR and age did not significantly correlate. However, late HMR significantly correlated with age after standardization: late HMR = - 0.0071 × age + 3.69 (r = 0.078, p = 0.028), indicating that a 14-year increase in age corresponded to a decrease in HMR of 0.1. Whereas the lower limit (2.5% quantile) of late HMR was 2.3 for all patients, it was 2.5 and 2.0 for those aged ≤ 63 and > 63 years, respectively. Early HMR tended to be lower in subjects with the higher age (p = 0.076), whereas WR was not affected by age.

Conclusion: While late HMR was slightly decreased in elderly patients, the lower limit of 2.2-2.3 can still be used to determine both early and late HMR.

Citing Articles

Cardiac sympathetic activity and lethal arrhythmic events: insight into bell-shaped relationship between I-meta-iodobenzylguanidine activity and event rates.

Nakajima K, Nakata T, Doi T, Verschure D, Frantellizzi V, De Feo M EJNMMI Res. 2024; 14(1):67.

PMID: 39033243 PMC: 11264658. DOI: 10.1186/s13550-024-01131-4.

Sympathetic I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging.

Nakajima K, Matsumura T, Komatsu J, Wakabayashi H, Ono K, Kinuya S Ann Nucl Med. 2024; 38(10):814-824.

PMID: 38869809 PMC: 11401792. DOI: 10.1007/s12149-024-01950-4.

Absolute quantitation of sympathetic nerve activity using [I] metaiodobenzylguanidine SPECT-CT in neurology.

Saito S, Nakajima K, Komatsu J, Shibutani T, Wakabayashi H, Mori H EJNMMI Rep. 2024; 8(1):15.

PMID: 38822219 PMC: 11143090. DOI: 10.1186/s41824-024-00205-9.

Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT.

Saito S, Nakajima K, Shibutani T, Wakabayashi H, Yoneyama H, Konishi T Ann Nucl Cardiol. 2023; 9(1):61-67.

PMID: 38058582 PMC: 10696146. DOI: 10.17996/anc.23-00002.

Montreal Cognitive Assessment Predicts the Short-Term Risk of Lewy Body Disease in Isolated REM Sleep Behavior Disorder with Reduced MIBG Scintigraphy.

Miyamoto M, Miyamoto T Mov Disord Clin Pract. 2023; 10(1):32-41.

PMID: 36698993 PMC: 9847289. DOI: 10.1002/mdc3.13569.

References

Verschure D, Veltman C, Manrique A, Somsen G, Koutelou M, Katsikis A . For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014; 15(9):996-1003. DOI: 10.1093/ehjci/jeu044. View

Nakajima K . Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010; 24(3):125-35. PMC: 2855806. DOI: 10.1007/s12149-009-0337-2. View

Estorch M, Carrio I, Berna L, Torres G . Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol. 1995; 2(2 Pt 1):126-32. DOI: 10.1016/s1071-3581(95)80023-9. View

Verschure D, Poel E, Nakajima K, Okuda K, van Eck-Smit B, Somsen G . A European myocardial I-mIBG cross-calibration phantom study. J Nucl Cardiol. 2017; 25(4):1191-1197. PMC: 6133137. DOI: 10.1007/s12350-017-0782-6. View

Chen W, Botvinick E, Alavi A, Zhang Y, Yang S, Perini R . Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging. J Nucl Cardiol. 2008; 15(1):73-9. DOI: 10.1016/j.nuclcard.2007.09.027. View

Chow L, Chow S, Anderson R, Gosling J . Autonomic innervation of the human cardiac conduction system: changes from infancy to senility--an immunohistochemical and histochemical analysis. Anat Rec. 2001; 264(2):169-82. DOI: 10.1002/ar.1158. View

Verschure D, de Groot J, Mirzaei S, Gheysens O, Nakajima K, van Eck-Smit B . Cardiac I-mIBG scintigraphy is associated with freedom of appropriate ICD therapy in stable chronic heart failure patients. Int J Cardiol. 2017; 248:403-408. DOI: 10.1016/j.ijcard.2017.08.003. View

Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S . Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008; 52(4):378-87. View

Pina I, Carson P, Lindenfeld J, Archambault W, Jacobson A . Persistence of I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from the ADMIRE-HF Trial). Am J Cardiol. 2016; 119(3):434-439. DOI: 10.1016/j.amjcard.2016.10.024. View

10.

Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M . Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2011; 39(1):113-9. DOI: 10.1007/s00259-011-1963-1. View

11.

Nakajima K, Verschure D, Okuda K, Verberne H . Standardization of I--iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications. Clin Transl Imaging. 2017; 5(3):255-263. PMC: 5437131. DOI: 10.1007/s40336-017-0230-2. View

12.

Orimo S, Suzuki M, Inaba A, Mizusawa H . 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18(5):494-500. DOI: 10.1016/j.parkreldis.2012.01.009. View

13.

Jacobson A, Chen J, Verdes L, Folks R, Manatunga D, Garcia E . Impact of age on myocardial uptake of ¹²³I-mIBG in older adult subjects without coronary heart disease. J Nucl Cardiol. 2013; 20(3):406-14. DOI: 10.1007/s12350-013-9701-7. View

14.

Agostini D, Verberne H, Burchert W, Knuuti J, Povinec P, Sambuceti G . I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2007; 35(3):535-46. DOI: 10.1007/s00259-007-0639-3. View

15.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S . A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6(7):772-84. DOI: 10.1016/j.jcmg.2013.02.007. View

16.

Klene C, Jungen C, Okuda K, Kobayashi Y, Helberg A, Mester J . Influence of ROI definition on the heart-to-mediastinum ratio in planar I-MIBG imaging. J Nucl Cardiol. 2016; 25(1):208-216. DOI: 10.1007/s12350-016-0708-8. View

17.

King A, Mintz J, Royall D . Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. 2011; 26(7):1218-24. DOI: 10.1002/mds.23659. View

18.

Okuda K, Nakajima K, Sugino S, Kirihara Y, Matsuo S, Taki J . Development and validation of a direct-comparison method for cardiac (123)I-metaiodobenzylguanidine washout rates derived from late 3-hour and 4-hour imaging. Eur J Nucl Med Mol Imaging. 2015; 43(2):319-325. DOI: 10.1007/s00259-015-3173-8. View

19.

Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K . Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2004; 32(2):186-94. DOI: 10.1007/s00259-004-1624-8. View

20.

Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K . Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016; 30(3):188-99. PMC: 4819542. DOI: 10.1007/s12149-016-1065-z. View